Denali Advisors LLC Takes Position in Amphastar Pharmaceuticals, Inc. $AMPH

Denali Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 135,000 shares of the company’s stock, valued at approximately $3,598,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its position in Amphastar Pharmaceuticals by 356.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after purchasing an additional 737 shares during the last quarter. Global Retirement Partners LLC increased its stake in shares of Amphastar Pharmaceuticals by 219.0% in the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after buying an additional 703 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 3,430.8% in the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after buying an additional 1,338 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Amphastar Pharmaceuticals by 75.7% in the second quarter. IFP Advisors Inc now owns 2,035 shares of the company’s stock valued at $52,000 after buying an additional 877 shares during the last quarter. Finally, State of Wyoming lifted its position in Amphastar Pharmaceuticals by 21.2% during the 3rd quarter. State of Wyoming now owns 3,301 shares of the company’s stock worth $88,000 after buying an additional 578 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 3.4%

Shares of NASDAQ AMPH opened at $28.50 on Monday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $32.69. The firm’s 50-day moving average is $26.97 and its 200-day moving average is $26.73. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $1.31 billion, a PE ratio of 12.61, a price-to-earnings-growth ratio of 5.20 and a beta of 0.88.

Analyst Ratings Changes

Several equities research analysts have weighed in on AMPH shares. Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Barclays began coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price target on the stock. Needham & Company LLC dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $31.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 9,787 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total transaction of $256,419.40. Following the completion of the sale, the executive vice president owned 138,043 shares in the company, valued at approximately $3,616,726.60. The trade was a 6.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $27.10, for a total value of $113,250.90. Following the completion of the transaction, the director owned 35,183 shares in the company, valued at $953,459.30. This represents a 10.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 18,129 shares of company stock valued at $477,176. 27.10% of the stock is currently owned by insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.